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 Abstract 
 
The synthesis, in silico studies, antiprotozoal and cytotoxic activities of eleven quinoline-biphenyl 
hybrids are described herein. The structure of the synthesized products was elucidated by a 
combination of spectrometric analyses. The synthesized compounds were evaluated against 
Plasmodium falciparum, and amastigotes forms both Leishmania (V) panamensis and Trypanosoma 
cruzi. Cytotoxicity was evaluated against human U-937 macrophages. Hybrid 4a showed similar 
activity than meglumine antimoniate and compound 4b exhibited an activity similar to that of 
benznidazole. Hybrid 4k showed the best activity against P. falciparum. Although these compounds 
were toxic for mammalian U-937 cells, however they may still have potential to be considered  as  
candidates  for  drug development because of their antiparasite activity. In addition, molecular docking 
was used to determine the in silico inhibition of some of the designed compounds against PfLDH and 
cruzipain, two important pharmacological targets involved in antiparasitic diseases. All hybrids were 
docked to the three-dimensional structures of PfLDH and T. cruzi cruzipain as enzymes using 
AutoDock Vina. Notably, the docking results showed that the most active compounds 4b (CE50: 11.33 
μg/mL for P.  falciparum) and 4k (CE50: 8.84 μg/mL for T. cruzi) showed the highest scoring pose (-
7.5 and -7.7 kcal/mol, respectively). This result show a good correlation between the predicted scores 
with the experimental data profile, suggesting that these ligands could act as competitive inhibitors of 
PfLDH or T. cruzi cruzipain enzymes, respectively. Finally, in silico ADMET studies of the quinoline 
hybrids showed that these novel compounds have suitable drug-like properties, making them 
potentially promising agents for antiprotozoal therapy. 
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Introduction  
 
Protozoal diseases (PD) are a diverse group of diseases which are the cause of a significant mortality 
rate in various developing countries of tropical and subtropical regions. PDs include, among others, 
Chagas’ disease (American trypanosomiasis), leishmaniasis and malaria which are caused by the 
parasitic protozoan of Trypanosoma cruzi (T. cruzi), Leishmania species and Plasmodium species, 
respectively (WHO 2018a). Human malaria is caused by at least five species of Plasmodium, the most 
important being P. falciparum and P. vivax (WHO 2018b). Leishmania (V) panamensis is one of the 
most prevalent Leishmania species involved in human cases of cutaneous leishmaniasis in Colombia 
and other countries in Central America (Alvar et al., 2012).  
  
Current chemotherapies are still based on old drugs such as pentavalent antimonials (meglumine 
antimoniate and sodium stibogluconate), pentamidine isethionate and amphotericin B to treat cutaneous 
leishmaniasis (WHO 2019a); nitroaromatic compounds (benznidazole and nifurtimox) for treatment of 
Chagas disease (WHO 2019b) or chloroquine, amodiaquine, sulfadoxine/pyrimethamine to treat P. 
falciparum or P. vivax malaria, respectively. More recently new artemisinin-based combination therapy 
is recommended for the treatment of P. falciparum (WHO 2018b). Unfortunately, all of these drugs 
have several toxic effects on the patients that are associated with high doses and length of therapeutic 
schemes. Moreover, they are no longer as effective as before due to the emergence of drug resistance in 
the parasite, which complicates the control of these diseases (Chatelain and Ioset, 2011; Den Boer et 
al., 2011; Keenan and Chaplin, 2015; Fidock et al., 2004). 
 
The quinolinic core is a structural feature of several bioactive compounds endowed with 
pharmacological activities such anti-mycobacterial, anti-microbial, anti-convulsant, anti-inflammatory 
and anti-tumor, among others (Suresh et al., 2009; Franck et al., 2004). Several compounds containing 
the quinolinic core also have antileishmanial, antitrypanosomal and antiplasmodial activities 
(Nakayama et al., 2005; Tempone et al., 2005; Dietze et al., 2001; Vieira et al., 2008; Cardona et al., 
2013; Palit et al., 2009; Egan 2001). Thus, quinoline based compounds 1a and 1b (fig. 1) were 
evaluated against L. (V) panamensis and T. cruzi and they showed to be active in both parasites (Coa et 
al., 2017; Coa et al., 2015). Artemisinin-aminoquinoline hybrid 1c (fig. 1) showed high antiplasmodial 
activity which was 9-fold higher than chloroquine (Lombard et al., 2011)  
 
 
On the other hand, natural compounds containing the biphenyl moiety, such as honokiol (1d) and 
schisandrin C (1e) have shown many relevant biological activities (Ma et al. 2011; Chen  et al. 2001). 
Another interesting compound is biphenyl derivative 1f, whose structure is based on that of 
methylglyoxal bis(guanylhydrazone). Compound 1f was active in vitro against several Trypanosoma 
species, including T. brucei rhodesiense and T. b. brucei (Brun et al. 1996). Finally, the furanchalcone-
biphenyl hybrid 1g, exhibited good activity against T. cruzi showing better activity than benznidazole 
(García et al., 2019) (fig. 1).  
 
 
 
Fig. 1 Biologically actives biphenyl and quinoline hybrids  
 
Hybrid molecules are chemical entities with two (or more than two) structural domains having different 
biological functions and that can, therefore, to show a dual mode of action acting as two distinct 
pharmacophores (Cardona-G et al. 2018; Meunier 2008) without necessarily acting on the same 
biological target (Dunn et al. 2016). A promising strategy based on these class of compounds has 
recently emerged in medicinal chemistry for the discovery and development of new drugs. In the search 
for new therapeutic alternatives to treat cutaneous leishmaniasis, Chagas disease and malaria, we 
designed and synthesized a series of quinoline-biphenyl hybrids, whose general structures are indicated 
in fig. 2, and their in vitro cytotoxicity, antileishmanial, antitrypanosomal and antiplasmodial activities 
was in turn evaluated by us. 
 
 
 
  
Fig. 2 Design of quinoline-biphenyl hybrids as antiprotozoal agents 
 
Material and methods 
Chemical synthesis 
General remarks 
Microwave reactions were carried out in a CEM Discover microwave reactor in sealed vessels 
(monowave, maximum power 300 W, temperature control by IR sensor, fixed temperature). 1H and 13C 
NMR spectra were recorded on a Varian instruments operating at 600 (300) MHz. The signals of the 
deuterated solvent (CDCl3) were used as reference (CDCl3:  = 7.27 ppm for 1H NMR and  = 77.00 
ppm for 13C NMR. Carbon atom types (C, CH, CH2, CH3) were determined by using the DEPT 
(Distortion less Enhancement by Polarization Transfer) or APT (Attached Proton Test) pulse sequence. 
High resolution mass spectra were recorded using electrospray ionization mass spectrometry (ESI-MS). 
A QTOF Premier instrument with an orthogonal Z-spray-electrospray interface (Waters, Manchester, 
UK) was used operating in the W-mode. The drying and cone gas was nitrogen set to flow rates of 300 
and 30 L/h, respectively. Methanol sample solutions (ca. 1 x 10-5 M) were directly introduced into the 
ESI spectrometer at a flow rate of 10 L/min. A capillary voltage of 3.5 kV was used in the positive 
scan mode, and the cone voltage set to Uc = 10 V. For accurate mass measurements, a 2 mg/L standard 
solution of leucine enkephalin was introduced via the lock spray needle at a cone voltage set to 85 V 
and a flow rate of 30 L/min. IR spectra were recorded on a Spectrum RX I FT-IR system (Perkin-
Elmer, Waltham, MA, USA) in KBr disks. Silica gel 60 (0.063-0.200 mesh, Merck, Whitehouse 
Station, NJ, USA) was used for column chromatography, and precoated silica gel plates (Merck 60 
F254 0.2 mm) were used for thin layer chromatography (TLC). 
General procedure for the synthesis of aryl-quinolines (4a-4K)  
A mixture of quinolin-8-yl trifluoromethanesulfonate (1 eq), boronic acid 6 a – k (2 eq), palladium 
acetate (5%), triphenylphosphine (10%), sodium carbonate (7eq) and 4 mL of n-propanol: distilled H2O 
(10:1), were heated under ultrasonic radiation for 60 minutes (50°C). Then the mixture was extracted 
with ethyl acetate and dried with Na2SO4 and filtered. The crude reaction mixture was evaporated 
under reduced pressure and the residue was purified by preparative TLC eluting with a mixture of 
hexane: ethyl acetate (7:3). The final product was dried to obtain the aryl-quinolines 4 a – k with yields 
ranging from 40% to 52%. 
8-phenylquinoline (4a): Yield 62% (0.47 mmol, 96.8 mg); beige oil; IR (cm−1): νmax, 1580 (C=N), 
1441 (C=CAr), 800 (C–HAr). 1H-NMR (CDCl3): δ 7.44 (1H, m), 7.49 (1H, d, J = 7.4 Hz), 7.58 (2H,t, J 
= 15.0 Hz), 7.33 (2H,m), 7.65 (1H, t, J = 15.2 Hz), 7.78 (3H, m), 7.85 (1H, dd, J = 8.0, 1.2 Hz), 8.22 
(1H, dd, J = 8.2, 1.7 Hz), 9.01 (1H, dd, J = 4.0, 1.7 Hz). 13C-NMR (CDCl3): δ 121.01 (CH), 126.29 
(CH), 127.40 (CH), 127.57 (CH), 128.03 (2CH), 128.74 (C), 130.34 (C), 130.66 (2CH), 136.28 (C), 
139.59 (C), 140.89 (C), 146.02 (C), 150.27 (CH). ESI–MS: m/z 206.0970 [M + H]+, Calc. For 
C15H11N: 206.0969. 
4-(quinolin-8-yl)phenol (4b): Yield 63% (0.48 mmol, 106.7 mg); yellow solid, m.p. 248–250 °C; IR 
(cm−1): νmax, 3058 (O-H), 1625 (C=N), 1500 (C=CAr), 1276 (C–O–C), 1230 (C-O), 809 (C–HAr). 1H-
NMR (CDCl3): δ 6.89 (2H,d, J = 7.8 Hz),  7.52 (2H,d, J = 8.0 Hz), 7.55 (1H, m), 7.65 (1H, m), 7.71 
(1H, d, J = 7.0 Hz), 7.92 (1H, d, J = 8.1 Hz), 8.40 (1H, dd, J = 8.3, 1.6 Hz), 8.90 (1H, dd, J = 4.1, 1.6 
Hz), 9.52 (1H, s). 13C-NMR (CDCl3): δ 115.07 (2CH), 121.71 (CH), 126.91 (CH), 127.50 (CH), 128.90 
(C), 129.97 (CH), 130.28 (C), 132.22 (2CH), 136.86 (CH), 140.32 (C), 145.75 (C), 150.39 (CH), 
157.22 (C). ESI–MS: m/z 222.0919 [M + H]+, Calc. For C15H11NO: 222.0916. 
 
8- (4-methoxyphenyl) quinoline (4c):  Yield 61% (0.46 mmol, 109.2 mg); yellow solid, m.p. 198–200 
°C; IR (cm−1): νmax, 1596 (C=N), 1441 (C=CAr), 817 (C–HAr). 1H-NMR (CDCl3): δ 3.83 (3H, s), 
7.05 (2H, d, J = 8.5 Hz), 7.56 (1H, m), 7.62 (2H, d, J = 8.5 Hz), 7.66 (1H, t, J = 15.3 Hz), 7.74 (1H, d, 
J = 7.0 Hz), 7.96 (1H, d, J = 8.1 Hz ), 8.42 (1H, d, J = 8.2 Hz), 8.90 (1H, dd, J = 4.1, 1.6 Hz). 13C-NMR 
(CDCl3): δ 55.16 (OCH3), 113.25 (2 CH), 121.35 (CH), 126.48 (CH), 127.38 (C), 128.45 (C), 129.70 
(CH), 131.44 (CH), 131.77 (2 CH), 136.47 (CH), 139.49 (C), 145.25 (C), 150.08 (CH), 158.59 (C).  
ESI–MS: m/z 236.1075 [M + H]+, Calc. For C16H13NO: 236.1072. 
2-(quinolin-8-yl)phenol (4d): Yield 62% (0.47 mmol, 105.0 mg); yellow solid, m.p. 250–252 °C; IR 
(cm−1): νmax, 3028 (O-H), 1610 (C=N), 1438 (C=CAr), 1267 (C–O–C), 1228 (C-O), 810 (C–HAr). 1H-
NMR (CDCl3): δ 7.08 (1H, t, J = 15.0 Hz), 7.19 (1H,d, J = 8.1 Hz),  7.40 (2H,t, J = 15.0 Hz), 7.43 (1H, 
d, J = 7.7 Hz), 7.53 (1H, m), 7.71 (1H, t, J = 15.3 Hz), 7.90 (2H, t, J = 14.4 Hz), 8.35 (1H, dd, J = 8.3, 
1.4 Hz), 8.93 (1H, dd, J = 4.1, 1.6 Hz), 10.77 (1H, s). 13C-NMR (CDCl3): δ 119.62 (CH), 120.93 (CH), 
121.12 (CH), 127.58 (CH), 127.80 (CH), 128.25 (C), 128.65 (C), 129.93 (CH), 132.62 (CH), 133.39 
(CH), 138.56 (CH), 138.95 (C), 145.31 (C), 149.25 (CH), 155.08 (C). ESI–MS: m/z 222.0919 [M + 
H]+, Calc. For C15H11NO: 222.0920. 
8-(4-fluorophenyl) quinoline (4e): Yield 59% (0.47 mmol, 96.8 mg); white solid, m.p. 164–166 °C; IR 
(cm−1): νmax, 1600 (C=N), 1400 (C=CAr), 820 (C–HAr). 1H-NMR (CDCl3): δ 7.29 (2H,t, J = 17.0 Hz), 
7.46 (1H,m), 7.66 (1H, t, J = 15.1 Hz), 7.77 (3H, m), 7.87 (1H, d, J = 8.0 Hz), 8.24 (1H, d, J = 8.2 Hz), 
9.02 (1H, dd, J = 4.0, 1.4 Hz). 13C-NMR (CDCl3): δ 114.76 (CH), 115.04 (CH), 121.05 (CH), 126.25 
(CH), 127.67 (CH), 128.73 (C), 130.17 (CH), 132.16 (CH), 132.26 (CH), 135.40 (C), 135.44 (C), 
136.29 (CH), 139.68 (C), 145.87 (C), 150.24 (CH). ESI–MS: m/z 224.0876 [M + H]+, Calc. For 
C15H10FN: 224.0875. 
8-(4-nitrophenyl) quinoline (4f): Yield 54% (0.41 mmol, 102.8 mg); yellow solid, m.p. 173–175 °C; IR 
(cm−1): νmax, 1595 (C=N),1510 (N-O), 1496 (C=CAr), 817 (C–HAr). 1H-NMR (CDCl3): δ 7.54 (1H, m),  
7.72 (2H,t, J = 15.3 Hz), 7.82 (1H, dd, J = 7.1, 1.4 Hz), 7.94 (2H, d, J = 8.8 Hz), 7.98 (1H, dd, J = 8.2, 
1.3 Hz), 8.32 (1H, dd, J = 8.3, 1.7 Hz), 8.40 (2H, d, J = 8.7 Hz), 9.00 (1H, dd, J = 4.1, 1.7 Hz). 13C-
NMR (CDCl3): δ 121.55 (CH), 123.22 (2CH), 126.34 (CH), 128.80 (C), 129.06 (CH), 130.47 (CH), 
131.56 (2CH), 136.53 (CH), 138.49 (C), 145.59 (C), 146.44 (C), 147.07 (C), 150.69 (CH). ESI–MS: 
m/z 251.0821 [M + H]+, Calc. For C16H13NO: 251.0820. 
8-(2,3-dimethoxyphenyl) quinoline (4g): Yield 55% (0.42 mmol, 111.4 mg); beig palid solid, m.p. 244–
246 °C; IR (cm−1): νmax 1583 (C=N), 1440 (C=CAr), 1233 (C–O–C), 800 (C–HAr). 1H-NMR (CDCl3): δ 
3.44 (3H, s), 3.91 (3H, s), 6.88 (1H, dd, J = 7.4, 1.6 Hz), 7.11 (1H, dd, J = 8.2, 1.6 Hz), 7.16 (1H, d, J = 
8.2 Hz), 7.50 (1H, m), 7.63 (2H, d, J = 5.08 Hz), 7.95 (1H, t, J = 9,7 Hz), 8.37 (1H, dd, J = 8.2, 1,6 
Hz), 8.74 (1H, dd, J = 4.2, 1.7 Hz). 13C-NMR (CDCl3): δ 54.44 (OCH3), 54.49 (OCH3), 98.39 (CH), 
104.32 (CH), 120.68 (CH), 121.28 (C), 126.08 (CH), 127.13 (CH), 128.65 (C), 131.35 (CH), 131.63 
(CH), 136.96 (CH), 137.98 (C), 146.24 (C), 149.12 (CH), 158.38 (C), 161.01 (C). ESI–MS: m/z 
266.1181 [M + H]+, Calc. For C17H15NO2: 266.1183. 
8-(2,4-dimethoxyphenyl) quinoline (4h): Yield 60% (0.46 mmol, 121.1 mg); beig palid solid, m.p. 240–
242 °C; IR (cm−1): νmax 1593 (C=N), 1492 (C=CAr), 1215 (C–O–C), 817 (C–HAr). 1H-NMR (CDCl3): δ 
3.62 (3H, s), 3.86 (3H, s), 6.63 (1H, dd, J = 8.1, 2.2 Hz), 6.66 (1H, d, J = 2.2 Hz), 7.16 (1H, d, J = 8.2 
Hz), 7.47 (1H, m), 7.59 (2H, t, J = 6.5 Hz), 7.88 (1H, m), 8.33 (1H, dd, J = 8.4, 1,4 Hz), 8.70 (1H, dd, J 
= 4.1, 1.6 Hz). 13C-NMR (CDCl3): δ 54.44 (OCH3), 54.49 (OCH3), 98.39 (CH), 104.32 (CH), 120.68 
(CH), 121.28 (C), 126.08 (CH), 127.13 (CH), 128.65 (C), 131.35 (CH), 131.63 (CH), 136.96 (CH), 
137.98 (C), 146.24 (C), 149.12 (CH), 158.38 (C), 161.01 (C). ESI–MS: m/z 266.1181 [M + H]+, Calc. 
For C17H15NO2: 266.1182. 
8-(2,5-dimethoxyphenyl) quinoline (4i): Yield 53% (0.41 mmol, 108.7 mg); beig palid solid, m.p. 246–
248 °C; IR (cm−1): νmax 1599 (C=N), 1441 (C=CAr), 1283 (C–O–C), 813 (C–HAr). 1H-NMR (CDCl3): δ 
3.57 (3H, s), 3.76 (3H, s), 6.84 (1H, d, J = 3.1 Hz), 6,97 (1H, dd, J = 9.0, 2.9 Hz), 7.02 (1H, d, J = 8.7 
Hz), 7.48 (1H, m), 7.60 (2H, d, J = 4.90 Hz), 7.91 (1H, t, J = 9,7 Hz), 8.34 (1H, dd, J = 8.2, 1,6 Hz), 
8.72 (1H, dd, J = 4.2, 1.7 Hz). 13C-NMR (CDCl3): δ 55.72 (OCH3), 56.14 (OCH3), 113.20 (CH), 
114.20 (CH), 118.28 (CH), 121.74 (CH), 126.98 (CH), 128.43 (CH), 129.56 (C), 130.63 (C), 131.99 
(CH), 137.88 (CH), 138.79 (C), 146.89 (C), 150.29 (CH), 152.63 (C), 154.48 (C). ESI–MS: m/z 
266.1181 [M + H]+, Calc. For C17H15NO2: 266.1183. 
8-(2,6-dimethoxyphenyl) quinoline (4j): Yield 50% (0.38 mmol, 100.8 mg); white solid, m.p. 238–240 
°C; IR (cm−1): νmax 1600 (C=N), 1441 (C=CAr), 1240 (C–O C), 798 (C–HAr). 1H-NMR (CDCl3): δ 3.66 
(6H, s), 6.76 (2H, d, J = 8.3 Hz), 7.39 (2H, m), 7.63 (2H, t, J = 7.08 Hz), 7.85 (1H, dd, J = 6.8, 2.9 Hz), 
8.19 (1H, dd, J = 8.2, 1.7 Hz), 8.88 (1H, dd, J = 4.2, 1.8 Hz). 13C-NMR (CDCl3): δ 55.73 (2 OCH3), 
104.17 (2CH), 120.38 (CH), 123.12 (C), 125.79 (CH), 127.14 (CH), 128.11 (C), 128.87 (CH), 131.31 
(CH), 134.18 (C), 135.85 (CH), 146.81 (C), 149.66 (CH), 157.94 (2C). ESI–MS: m/z 266.1181 [M + 
H]+, Calc. For C17H15NO2: 266.1178. 
 
8-(3,4-dimethoxyphenyl) quinoline (4k): Yield 65% (0.50 mmol, 132.6 mg); white solid, m.p. 243–245 
°C; IR (cm−1): νmax 1568 (C=N), 1441 (C=CAr), 1276 (C–O C), 815 (C–HAr). 1H-NMR (CDCl3): δ 3.94 
(3H, s), 3.96 (3H, s), 7.04 (1H,d, J = 8.1), 7.33 (2H,m), 7.41 (1H, m), 7.60 (1H, t, J = 15.1 Hz), 7.80 
(2H,m), 8.18 (1H, dd, J = 8.4, 1.6 Hz), 8.99 (1H, dd, J = 4.1, 1.6 Hz). 13C-NMR (CDCl3): δ 55.68 
(OCH3), 55.69 (OCH3), 110.73 (CH), 113.95 (CH), 120.74 (CH), 122.78 (CH), 126.05 (CH), 127.04 
(CH), 128.55 (C), 129.85 (CH), 132.03 (C), 136.08 (CH), 140.33 (C), 145.83 (C), 148.14 (C), 148.31 
(C), 149.94 (CH). ESI–MS: m/z 266.1181 [M + H]+, Calc. For C17H15NO2: 266.1180. 
  
Biological activity assays 
In vitro Cytotoxicity  
The cytotoxic activity of the compounds was assessed in the human promonocytic cell line U-937 
(ATCC CRL-1593.2TM) based on the viability evaluated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay as described elsewhere (Taylor et al. 2011). Briefly, U-937 cells 
grown in tissue flasks were harvested and washed with phosphate buffered saline (PBS) by 
centrifugation. Cells were counted and adjusted at 1×106 cells/mL of complete culture medium (RPMI-
1640 supplemented with 10% Fetal Bovine Serum-FBS and 1% of antibiotics -100 U/mL penicillin and 
0.1 mg/mL streptomycin.  One hundred µL of cell suspension were dispensed into each well of a 96-
well cell-culture plate and then 100 L of two-fold serial dilutions of the compounds (starting at 200 
µg/mL) in complete RPMI 1640 medium were added. Plates were incubated at 37 °C, 5% CO2 during 
72 h in the presence of compounds. Then, 10 µL/well of MTT solution (0.5 mg/mL) was added into 
each well and plate was incubated at 37 °C for 3h. The formazan crystals were dissolved by adding 100 
µL/well of dimethyl sulfoxide and 30 min incubation. Cell viability was determined according to the 
intensity of color (absorbance) registered as optical densities (O.D) obtained at 570 nm in a 
spectrophotometer (Varioskan™ Flash Multimode Reader - Thermo Scientific, USA). Cells cultured in 
absence of compounds were used as control of viability (negative control), while doxorrubicin was 
used as control for cytotoxic drugs. Non-specific absorbance was corrected by subtracting the O.D of 
the blank. Assays were conducted in two independent runs with three replicates per each concentration 
tested. 
 
 In vitro antileishmanial activity 
   The activity of compounds was evaluated on intracellular amastigotes of  L. (V) panamensis 
transfected with the green fluorescent protein gene (MHOM/CO/87/UA140-EGFP) (Pulido et al., 
2012). The effect of each compound was determined according to the inhibition of the infection 
evidenced by both decrease of the infected cells and decrease of intracellular parasite amount. Briefly, 
U-937 human cells at a concentration of 3 × 105 cells/mL in RPMI 1640 containing 0.1 μg/mL of 
phorbol-12-myristate-13-acetate (PMA) were dispensed into each well of a 24-well cell culture plate 
and then infected with 5 days-old promastigotes in a 15:1 parasites per cell ratio. Plates were incubated 
at 34 °C, 5% CO2 during 3h and cells were washed two times with PBS to eliminate not internalized 
parasites. One mL of fresh complete RPMI 1640 medium supplemented with 10% FBS and 1% 
antibiotics was added into each well, cells were incubated again to guarantee multiplication of 
intracellular parasites. After 24 h of infection, culture medium was replaced by fresh culture medium 
containing each compound at 50-6.12 and 1.56 μg/mL and plates were incubated at 37 °C, 5% CO2. 
After 72 h, inhibition of the infection was determined. For this, cells were removed from the bottom 
plate with a trypsin/EDTA (250 mg) solution; recovered cells were centrifuged at 1100 rpm during 10 
min at 4 °C, the supernatant was discarded and cells were washed with 1 mL of cold PBS and 
centrifuged at 1100 rpm during 10 min at 4 °C. The supernatant was discarded and cells were 
suspended in 500 μL of PBS and analyzed by flow cytometry (FC 500MPL, Cytomics, Brea, CA, US). 
All determinations for each compound including  and standard drugs were carried out in triplicate, in 
two independent experiments (Buckner et al., 1996; Pulido et al., 2012). Activity of tested compounds 
was carried out in parallel with infection progress in culture medium alone and in culture medium with 
amphotericin B and meglumine antimoniate as antileishmanial drugs (positive controls).  
 
In vitro antitrypanosomal Activity  
T. cruzi, Tulahuen strain transfected with β-galactosidase gene (donated by Dr. F. S. Buckner, 
University of Washington) were maintained in vitro as epimastigotes by culturing in modified Novy-
MCNeal-Nicolle (NNN) medium. The U-937 cells were adjusted at 2.5×106 cells/mL of complete 
RPMI-1640 medium containing 0.1 μg/mL of phorbol myristate acetate to induce differentiation to 
macrophages. Then, 100 μL of this cell suspension were dispensed into each well of a 96-well cell-
culture plate. After 24 h of incubation at 37 °C, 5% CO2, macrophages were infected with early 
stationary growth phase (10 days in culture) epimastigotes, at the concentration of 12.5x105 
parasites/mL of complete RPMI 1640 medium equivalent to 5:1 (parasites per cell) ratio. Plates were 
incubated at 34 °C, 5% CO2 during 24 hours to allow the conversion to intracellular amastigotes. 
Extracellular parasites were removed by washing twice with 100 μL of PBS.  Then, 100 μL of each 
concentration (100 – 25 – 6.12 and 1.56 μg/mL) of compounds were added to infected cells, plates 
were incubated at 34 °C, 5% CO2. After 72 h of incubation plate wells were washed twice with PBS 
and the β-galactosidase activity was measured by spectrophotometry adding 100 μM of the 
chromogenic substrate CPRG (chlorophenol red-beta-D-galactopyranoside) and 0.1% nonidet P-40 to 
each well. After 3 h of incubation at 25 °C, absorbance was read at 570 nm in a spectrophotometer 
(Varioskan™ Flash Multimode Reader - Thermo Scientific, USA). Infected cells exposed to 
benznidazole were used as control for antitrypanosomal activity (positive control) while infected cells 
incubated in complete RPMI 1640 culture medium were used as control for infection (negative 
control). Non-specific absorbance was corrected by subtracting the O.D of the blank. Determinations 
were done by triplicate in at least two independent experiments (Insuasty et al. 2015). 
 
In vitro Antiplasmodial Activity 
The antiplasmodial activity was evaluated in asynchronic cultures of P. falciparum (NF54 strain), 
maintained in standard culture conditions. The effect of each compound over the growth of the 
parasites was determined by Plasmodium lactate dehydrogenase assay (pLDH) (Nkhoma et al. 2007; 
Londoño et al., 2016). Parasites  were plated  in  the  trophozoite  phase  at  1%  hematocrit  and  0.5 
%parasitemia in 100 L of each compound at an defined concentration (1000 – 25 – 6.25 – 1.56 
ug/mL). Plates were incubated in an atmosphere with a gas mixture of 4% O2, 3% CO2, and 97% N2, 
and incubated at 37°C for 72 hours. Meanwhile, two reagents  for  detecting  and  measuring  the  LDH  
enzyme  were prepared.  The  first  of  these  was  the  Malstat  reagent (400 L of Triton X-100 in 80 
mL of deionized water, 4.0 g L-lactate , 1.32 g Tris buffer and  0.022  g  of  3-acetylpyridine  adenine  
dinucleotide (APAD),  adjusting  the  pH  to  9  with  hydrochloric  acid,  and a volume of 200 mL with 
deionized water. The second reagent is NBT/PES solution (1-6 g  nitro blue tetrazolium salt and 0.008 
g phenazine ethosulfate  in 100 mL of deionized water. The solution was stored in a foil-covered 
container and kept at 4°C  until  required.  When  incubation  was complete,  plates  were  harvested  
and  subjected  to  three  20-minute freeze–thaw cycles to resuspend the culture. Thereafter, 100 L of 
Malstat reagent and 25 L of NBT/PES solution  were  added  to  each  well  of  a  new,  duplicate  
flat-bottomed 96-well microtiter plate. The culture in each of the wells of the original plate was 
resuspended by mixing with a multichannel  pipette.  Thereafter,  15 L  of  the  culture  was taken 
from each well and added to the corresponding well of the  Malstat  plate,  thereby  initiating  the  LDH  
reaction.  Color  development  of  the  LDH  plate  was monitored colorimetrically at 650 nm in the 
Varioskan Flahs readet after an hour of incubation in the dark.  
Data Analysis  
Cytotoxicity was determined according to cell growth (viability) and mortality percentages obtained for 
each isolated experiment (compounds, doxorubicin and culture medium). Results were expressed as 50 
lethal concentrations (LC50), corresponding to the concentration necessary to eliminate 50% of cells, 
calculated by Probit analysis (Finney, 1978). Percentage of viability was calculated by Equation 1, 
where the optical density (O.D) of control corresponds to 100 % of viability (cell growth).  
% Mortality = 1 – [(O.D Exposed cells) / (O.D Control cells) × 100] (1) 
Antileishmanial activity was determined according to percentage of infected cells and parasite amount 
obtained for each experimental condition by flow cytometer. The percentage of infected cells was 
determined as the number of positive events by green fluorescence (parasites) and forward side sctter 
dotplot analysis. On the other hand, the parasitic amount was determined by analysis of mean 
fluorescence intensity (MFI) (Pulido  et al., 2012). 
The parasitemia inhibition was calculated by equation 2, where the MFI of control corresponds to 
100% of parasitemia. In turn, inhibition percentage corresponds to 100 – % Parasitemia. Results of 
antileishmanial activity was expressed as 50% effective concentrations (EC50) determined by the Probit 
method (Finney, 1978):  
% inhibition  = 1 – [ (MFI Exposed parasites) / (MFI Control parasites) × 100] (2) 
Similarly, antitrypanosomal activity was determined according to the percentage of infected cells and 
parasite amount obtained for each experimental condition by colorimetry. The parasite inhibition was 
calculated by equation 3, where the O.D of control corresponds to 100% of parasites. Results of 
antitrypanosomal activity were also expressed as EC50 determined by the Probit method (Finney, 
1978):  
% inhibition = 1 – [(O.D Exposed parasites) / (O.D Control parasites) × 100] (3) 
The antiplasmodial activity of each compound was evidenced by the reduction of the O.D. The 
inhibition of parasitemia percentage was calculated by equation 3.  
The cytotoxicity was graded according to the LC50 value as high cytotoxicity: LC50 < 100 μg/mL, 
moderate cytotoxicity: LC50 > 100 to < 200 μg/mL, and potentially non-cytotoxicity: LC50 > 200 
μg/mL.  
Antiprotozoal activity (antileishmanial, antitrypanosomal or antiplasmodial) was graded according to 
the EC50 or IC50 values as high activity: EC50 < 20 μg/mL, moderate activity: EC50 > 20 to < 50 μg/mL, 
potentially non activity: EC50 > 100 μg/mL. The selectivity index (SI), was calculated by dividing the 
cytotoxic and the activity using the following formula: SI = LC50 / EC50 (Coa et al., 2017). 
 
Molecular docking studies 
Protein Structure and Setup 
To explore the potential mechanism of action of the hybrids 4a-k against two principal targets for 
antiparasitic drugs, the crystals structures of P. falciparum Lactate Dehydrogenase (pfLDH) enzyme in 
complex with their cofactor NADH and the structure of cruzipain, the mayor papaine-like cysteine 
protease in T.cruzi were obtained from the Protein Data Bank (PDB entry code 1LDG and 3I06, 
respectively) (Dunn et al., 1996). Discovery Studio (DS) Visualizer 2.5 was used to edit the protein 
structure to remove water molecules together with bound ligands. For docking studies on pfLDH in the 
absence of cofactor, the NADH cofactor was also removed. Both, the structures of the selected proteins 
were parameterized using AutoDock Tools (Morris et al., 2009). In general, hydrogens were added to 
polar side chains to facilitate the formation of hydrogen bonds, and the Gasteiger partial charges were 
calculated.  
 
Ligand dataset preparation and optimization 
Ligands used in this study are the new quinoline-hybrids 4a-k, quinoline-based drugs that have been 
used in the treatment of malaria (amodiaquine, mefloquine, quinine and chloroquine) and the cofactor 
NADH for comparison in the malaria-case. DS visualizer was used to rewrite the data files into pdb 
format. The structures of the ligands were parameterized using AutodockTools to add full hydrogens to 
the ligands, to assign rotatable bonds, to compute Gasteiger partial atomic charges and save the 
resulting structure in the required format for use with AutoDock. All possible flexible torsions of the 
ligand molecules were defined using AUTOTUTORS in AutoDockTools (Morris et al., 2009; Morris et 
al., 1998) to facilitate the simulated binding with the receptor structure. 
 
Docking and subsequent analysis 
Docking simulations were performed with AutoDock 5.6 using the Lamarkian genetic algorithm and 
default procedures for docking a flexible ligand to a rigid protein were followed. First, the Metapocket 
2.0 server (Huang 2009) was used to identify the best candidates to protein binding pockets by 
predictive calculation of the topology of tertiary structures of selected subunits. According to standard 
program parameters, five binding pockets were calculated in the protein model and reliability of the 
model was reviewed through the Z-value statistical test. Second, once potential binding sites were 
identified, docking of ligands to these sites was carried out to determine the most probable and most 
energetically favorable binding conformations. For this more rigorous docking simulations involving a 
smaller search space limited to the identified binding site, AutodockVina (Trott and Olson 2010) was 
used. The exhaustiveness (internal number of repetitions) was 20 for each protein-compound pair. The 
active site was surrounded by a docking grid of 24Å3 with a grid spacing of 1Å. In addition, five 
replicas per compound were calculated to obtain the final docking scores in kcal/mol. Docking 
solutions obtained from all molecules analyzed were ranked by the affinity scores given by AutoDock 
Vina based on the free energy binding theory (more negative score indicates higher affinity). Resulting 
structures and some of the docked conformations were graphically inspected to check the interactions 
using DS visualizer. 
 
Ligands drug likeness evaluation 
In silico drug-likeness prediction along with further ADMET (absorption, distribution, metabolism, 
excretion and toxicity) tools presents an array of opportunities which help in accelerating the discovery 
of new antiparasitic drugs. To find out the drug like properties 11 quinoline-hybrids 4a-k were 
screened for their pharmacokinetic properties using opensource cheminformatics toolkits such us 
Molinspiration software (for: MW, rotatable bonds and topographical polar surface area (PSA) 
descriptors, ALOGPS 2.1 algorithm from the Virtual Computational Chemistry Laboratory (for: Log 
Po/w descriptor) and Pre-ADMET 2.0 program to predicted various pharmacokinetic parameters and 
pharmaceutical relevant properties such as apparent predicted intestinal permeability (App. Caco-2), 
binding to human serum albumin (Khsa), MDCK cell permeation coefficients and intestinal or oral 
absorption (%HIA, %F). These important parameters define absorption, permeability, movement and 
action of drug molecule. The interpretation of two predicted ADMET properties using the Pre-ADMET 
program was as shown below:  
 
Value of Caco-2 permeability is classified into three classes: 
(1) If permeability < 4, low permeability; (2) if permeability < 70, moderate permeability; and (3) if 
permeability > 70, higher permeability.  
 
Value of MDCK cell level of permeability can be classified into three classes: 
(1) If permeability < 25, low permeability; (2) if 25 < permeability < 500, moderate permeability; and 
(3) if permeability > 500, higher permeability. 
 
 
Results and Discussion 
Chemistry 
The synthetic strategy for the preparation of quinoline-biphenyl hybrids is shown in Scheme 1. 
Thus, reaction of 8-hydroxyquinoline (1) with triflic anhydride yielded triflate 2 (80% yield, this 
compound has been already reported previously, Lord et al. 2009). Ultrasound assisted Suzuki cross-
coupling reaction of compound 2 with boronic acids 3 a– k (García et al. 2019) afforded quinoline-
byphenyl hybrids 4 a – k in 53 – 65%. Other methodologies that involved microwave irradiation, long 
refluxing times Pierson et al. 2010), other bases (Yang et al. 2016) or solvent change (Liu et al. 2005), 
were used, however the results did not improve those obtained with the method described above. 
 
 
Scheme 1 Synthetic pathway to quinoline-biphenyl hybrids  
 
The structure of each compound was elucidated by a combined study of IR, ESI-MS, 1H NMR, 13C 
NMR and bidimensional analysis. The IR spectra exhibit characteristic absorption peaks corresponding 
to C=N, C=CAr, C-O-C and C-HAr.  ESI-MS spectra exhibit characteristic [M+H]
+ peaks corresponding 
to their molecular weights. The assignation of all the signals to individual H or C- atoms was based on 
typical -values and J-constant coupling.  1H-NMR and 13C-NMR spectrum showed signals 
corresponding to –OCH3, –C=C–H of aryl group and quinoline.  
 
Biological activities 
 
    All compounds were subjected to in vitro evaluation of their cytotoxicity, antileishmanial, 
antitrypanosomal and antiplasmodial activity against U-937 human macrophages, intracellular 
amastigotes of L. (V) panamensis, intracellular amastigotes of T. cruzi and plasmodium falciparum, 
respectively. The results are summarized in the tables 1 and 2.  
 
    The antileishmanial, antitrypanosomal and antiplasmodial activities were measured by determining 
the EC50 that corresponds to the concentration of drug that gives the half-maximal reduction of the 
amount of parasites (Table 1). Dose-response relationship showed that compounds 4a,4b, 4e, 4f and 4k 
were active against intracellular amastigotes of L. (V) panamensis with EC50 < 20 μg/mL. The most 
active hybrid was 4a an EC50 of 8.95 ± 0.87 μg/mL which is comparable to referential drug meglumine 
antimoniate (EC50 = 9.4 ± 2.1 μg/mL).  Compounds 4c, 4d, 4h and 4i showed a moderated activity. 
Finally, hybrids 4g and 4j were not active. 
 
Table 1 In vitro antiprotozoal activity of quinoline-biphenyl hybrids 
 
Compound 
Antileishmanial activity 
(µg/mL, µM) 
Antitrypanosomal activity 
(µg/mL, µM) 
 Antiplasmodial activity 
(µg/mL, µM) 
EC50 a EC50  EC50 
4a  8.95 + 0.87, 43.62 32.68 + 3.79, 159.19  21.61 ± 2.48, 105.30 
4b 15.34 + 2.70, 69.34 8.84 + 0.94, 39.96  32.52 ± 1,05, 146.97 
4c 33.63+ 1.85, 142.91 186.69 + 13.26, 793.46  30.44 ± 3.40, 129.38 
4d 25.27 + 5.22, 114.05 34.62 + 5.51, 156.24  15.25 ± 1.39, 68.83 
4e 17.01 + 1.50, 76.19 34.50 + 3.94, 154.53  15.72 ± 2.62, 70.40 
4f 13.86 + 1.79, 55.39 50.19 + 8.39, 200.55  12.40 ± 1.19, 49.53 
4g 127.85 + 50.85, 481.88 74.91 + 8.54, 282.33  58.40 ± 5.13, 220.11 
4h 26.46 + 0.29, 99.72 75.45 + 8.57, 284.38  20.78 ± 2.86, 78.32 
4i 41.27 + 2.98, 155.57 45.69 + 5.18, 172.23  31.90 ± 5.97, 120.23 
4j  100.96 + 98.41, 380.55 35.94 + 3.78, 135.47  51.65 ± 5.80, 194.69 
4k 16.26 + 1.67, 61.30 17.88 + 0.97, 67.38  11.33 ± 1.07, 42.70 
Meglumine 
antimoniate b 
9.4 + 2.1, 25.68  NAc  NAc 
Amphotericin B  0.05 + 0.01, 0.054 NAc  NAc 
Benznidazole NAc 10.5 ± 1.8, 40.3  NAc 
Chloroquine  NAc NAc  3.35 ± 0.40, 10.47 
 
Data represent mean value +/- standard deviation; a EC50: Effective Concentration 50; b The molecular weight (MW) of MA 
is 365.98 g/mol (PubChem Compound Database, CID 64953, National Center for Biotechnology Information) 
(pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=64953); c NA: Not applicable. Active compounds: EC50 < 20 μg/mL. 
 
 
    Compounds 4b and 4k were active against intracellular amastigotes of T. cruzi. Hybrid 4b showed 
an activity similar to benznidazole (EC50 = 8.84 ± 0.94 vs 10.5 ± 1.8 μg/mL, respectively). Molecules 
4a, 4d, 4e and 4j exhibited moderated antitrypanosomal activity. In the same way, we observed that the 
compounds with higher activity against P. falciparum were 4d-4f and 4k, being the hybrid 4k the most 
active with an IC50 of 11.33 ± 1.07 μg/mL. 
 
Compounds 4a,4b, 4d-4f, 4i-4k and amphotericin B showed highly cytotoxic to U-937 cells showing 
LC50 < 100 μg/mL. Hybrids 4c, 4g, 4h and benznidazole, exhibited moderate cytotoxicity evidenced by 
LC50 values higher than 100 μg/mL. In turn, meglumine antimoniate showed no cytotoxicity (LC50 > 
200.0 μg/mL) (Table 2). 
 
    Overall, the anti-protozoal activity of the compounds was higher than their cytotoxicity. Thus, the 
calculated SI (Selectivity Index) values for these hybrids were >1. As demonstrated elsewhere, 
amphotericin B and meglumine antimoniate have very high SI values. Although hybrids 4a, 4b and 4k 
showed activity comparable to that of meglumine antimoniate, benznidazole and chloroquine, 
respectively, the SI of these compounds is affected by their high cytotoxicity. These results suggest that 
the biological activity of the quinoline derivatives reported here, except for 4g and 4j, is selective and 
more active against L. (V) panamensis than U-937 cells. Compounds 4b, 4d, 4e and 4g-4i were more 
actives against T. cruzi parasites than U-937 cells. On the other hand, hybrids 4a, 4c-4i and 4k, showed 
selectivity against P. falciparum. In this sense, compound 4h exhibited the best SI on both L. (V) 
panamensis and P. falciparum, with 4.78 and 6.08 values, respectively (Table 2).  
 
 
 
 
 
 
 
Table 2 In vitro cytotoxicity and selectivity index of biphenyl hybrids 
 
 
Compound 
Cytotoxicity 
(U-937 cells) 
(µg/mL, µM) 
L. (V) 
Panamensis 
T. Cruzi P. falciparum 
 
 
 
LC50 a SIb SI SI 
4a  27.31 + 8.64, 5.61 3.05 0.83 1.26  
4b 20.39 + 4.33, 92.14 1.33 2.31 0.63  
4c 133.11 + 32.78, 565.75 3.96 0.71 4.37  
4d 42.93 + 5.25, 193.72 1.70 1.24 2.81  
4e 62.91 + 22.55, 281.81 3.70 1.82 4.0  
4f 28.07 + 0.89, 112.16 2.02 0.56 2.26  
4g 120.39 + 20.76, 453.76 0.94 1.60 2.06  
4h 126.51 + 16.18, 476.84 4.78 1.68 6.08  
4i 67.30 + 15.40, 253.67 1.63 1.47 2.1  
4j  22.24 + 1.50, 83.81 0.22 0.61 0.43  
4k 16.38 + 3.71, 61.76 1.01 0.72 1.44  
Meglumine 
antimoniate c 
416.4 + 66.6; 1137.80 44.3 NAd NAd  
Amphotericin B  42.1 + 2.0, 45.6 842 NAd NAd  
Benznidazole 179.0 ± 4.2, 687.8 NAd 17.0 NAd  
Chloroquine 155.23 ± 5.20, 485.3 NAd NAd 12.78  
 
Data represent mean value +/- standard deviation; a LC50: Lethal Concentration 50;  b SI: Selectivity Index = LC50 / EC50; c 
The molecular weight (MW) of MA is 365.98 g/mol (PubChem Compound Database, CID 64953, National Center for 
Biotechnology Information) (pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=64953); d NA: Not applicable.  
 
 
SAR analysis showed that 4a, bearing an unsubstituted phenyl group, was the most active in L. (V) 
panamensis. Compound 4b, with a hydroxyl group in the 4-position is most active than compound 4c 
with a methoxy instead of the hydroxy group. The activity decreases when the hydroxy group was 
changed from 4-position to 2-position (4b vs 4d). Electron withdrawing groups in 4-position increase 
the activity over the electron donating methoxy group (4e and 4f vs 4c).  
 
As regards T. cruzi, we found that 4b was the most active compound. Changing the position of the 
hydroxyl group (4d) or the presence of electron withdrawing groups (4e and 4f) decrease the activity. 
The methylation of the hydroxyl group (4c) leads to the loss of activity. These results agree with other 
reports for several chalcones, coumarins, cinnamic ester and triclosan-caffeic acid hybrids (Brenzan et 
al. 2008; Aponte et al. 2010; Otero et al. 2014; Otero et al. 2017; García et al. 2018). The effect of the 
hydroxyl groups may be due to a better molecular recognition ability towards target bioreceptors upon 
hydrogen bond formation (Patrick 2013). In both protozoal disease, all disubstituted hybrids, with 
exception of 4k, exhibited low activity. Overall, monosubstituted compounds (4a-4f) showed better 
activity than disubstituted hybrids (4g-4j) 
 
On the other hand, we found that the presence of methoxyl groups in 3- and 4- position (4k) is very 
important for the antiplasmodial activity. This activity decreased when the methoxyl groups were 
changed to 2,4- (4h), 2,5-(4i), 2,6-(4i) and 2,3-(4g) positions.  The activity is also related to the 
presence in 4-position of electron withdrawing groups, such as nitro and fluorine groups, and the 
presence of the hydroxyl electron donating group in  2-position, as it appears in compound 4d. Electron 
donating groups, hydroxyl and methoxyl groups in the 4-position, such as in 4c and 4d, lead to a 
decrease in activity. 
 
Docking studies against PfLDH structure and binding pose prediction 
 
The P. falciparum lactate dehydrogenase enzyme (PfLDH) has been is considered as a potential 
molecular target for antimalarials, since it is a key enzyme that catalyses the interconversion of 
pyruvate and lactate with concomitant interconversion of NADH and NAD+ and provides the energy 
for the survival of the parasite. One of the products of hemoglobin degradation by malarial parasites is 
the ferriprotoporphyrin IX (hematin), which intoxicates the parasite by competing with NADH for the 
active site of PfLDH. Parasite survival depends on polymerization of hematin to hemozoin. The 
quinoline derivatives are believed to form complexes with the dimeric hematin, preventing the 
formation of hemozoin (Egan and Ncokazi 2005). Our present work used docking studies to select 
potential inhibitors of PfLDH based on quinoline hybrids as ligands, which were in vitro tested for its 
antimalarial activity against P. falciparum. Thus, docking studies are carried out to investigate the 
intermolecular interactions between the active ligands and the receptor PfLDH. The PfLDH enzyme 
possesses two important binding pockets, the cofactor (NADH) binding pocket (Site A) the allosteric 
binding pocket and (Site B). Using the Metapocket server, two potential binding sites for each ligand 
have been identified, one of them resulted in the NADH-binding site. This Site 1 is a binding pocket on 
the N-terminal end of the enzyme comprising amino acid residues Gly27, Ser28, Gly29, Phe52, Asp53, 
Ile54, Thr97, Ala98, Gly99, Phe100, Thr139, and Asn140. Site 2 was identified as the allosteric-
binding pocket near the surface end of enzyme constituted by amino acid residues Asp230, Lys198, 
Val233, Lys314, Glu317, Asp230, Leu201, Glu226, Phe229, Val200, Leu237, and Asn241 (fig. 3). 
Then, the 11 hybrids of quinoline were docked, with the cofactor absent, into both active sites of 
PfLDH (PDB code 1LDG) using AutoDock Vina. 
 
 
 
 
 
 
 
 
 
 
 
 
SITE 1 
SITE 2 
A B 
  
Fig.3 (A) Shows the most active compound against malaria parasite 4k (in red) in the two binding surface sites present in 
PfLDH enzyme: Site 1 is the natural NADH-binding site and Site 2 refers to the potential allosteric binding site. (B) Shows 
the most active compound 4b against T. cruzi parasite in the best binding site of T. cruzi cruzipain. 
 
 
 
When the cofactor was absent a comparable binding within the NADH-binding site and the allosteric 
site was achieved for all ligands, showing that the NADH-binding pocket (Site 1)  was the preferred 
binding site for all the ligands studied. The most active compound 4k (CE50: 11.33 μg/mL, Malaria 
parasite) fitted well in the NADH pocket (Docking score of -7.7 kcal/mol) and showed the best docking 
energy values among all hybrids, that is, close to NADH (which has a docking energy of -9.4 
kcal/mol). For comparison, docking score affinities against PfLDH structure for four quinoline-based 
market drugs (inhibitors used for malaria treatment) were also calculated in this study. It has been 
shown that the chloroquine interacts specifically with PfLDH in the NADH binding site, occupying a 
position analogous to that of the adenyl ring cofactor and therefore acts as a competitive inhibitor, 
suggesting that the mechanism of parasite growth inhibition by the different compounds results from 
drug competition with NADH for the PfLDH (Read et al. 1999; Vennerstrom et al. 1999; Menting et al. 
1997). For all hybrids studied, there was comparable docked solutions within the cofactor-binding site 
similar to that of drugs currently used. In the absence of the cofactor, the most stable bound 
conformation of the hybrid 4k (the docking score was -7.7 kcal/mol) showed higher affinity than that 
observed for the marketed drugs chloroquine, amodiaquine and quinine (docking energy of -7.4, -7.4 
and -7.1 kcal/mol, respectively). The binding energies for representative ligand structures, as calculated 
by Autodock, are given in Table 3. The superposition of  NADH (in blue) and the best conformation 
obtained theoretically for all hybrids (in red), shown in Figure 1, reveals that ligands endowed with 
conformational mobility (calculated in this docking study) can rearrange themselves into favorable 
conformations in order to fill the cofactor-binding site. 
 
All ligands studied showed good binding affinity compared to NADH in the NADH-binding pocket 
pointing to a possible competitive inhibition. In general, the compounds docked similarly across the 
delimited binding site, with a set of hydrophobic interactions that potentially confers stability during 
the binding event. The molecules also form diverse types of interactions, especially π–anion between 
aryl ring of hybrids and carboxylic group of Asp53 residue in the protein, π–sigma interaction between 
aromatic quinoline ring and the catalytic residues Ala98 and Ile54, located adjacent to the nicotinamide 
end of the cofactor-binding domain. The best docked conformation of  highly active molecule 
(compound 4k) and the active site residues that interact inside PfLDH are shown in Figure 4A and 
Figure 4B. According to these docking results, PfLDH could be a potential therapeutic target for the 
evaluated hybrids, despite the fact that the docking scores when compared to natural ligand NADH 
showed highest binding values than the typical antimalarial-drugs. In addition, docking studies showed 
that the affinity of the designed hybrids is correlated with the results obtained from in-vitro studies.  
 
 
 
 
Fig 2 (A) Superposition of the best conformation of a set hybrids 4a-k (in red) and NADH (in blue) in the NADH-binding 
site of P. falciparum lactate dehydrogenase (PfLDH enzyme PDB: 1LDG). (B) 2D representation of interactions formed by 
the most active compound against malaria parasite 4k with aminoacids of the enzyme. (C) The best conformation of the 
most active hybrid against T. cruzi parasite 4b (in red) within active site of T. cruzi cruzipain structure (PDB:3I06). (D) 2D 
representation of interactions formed by the most active compound against T. cruzi parasite 4b with aminoacids of the 
cruzipain enzyme. 
  
 
 
 
 
 
 
Docking of hybrids on Cruzipain active site and binding pose prediction 
Cysteine proteases are essential for T. cruzi survival. Among them, cruzipain is a relevant protein target 
to design novel inhibitors for Chagas disease treatment (Otto and Shirmeister 1997; Sajid and 
McKerrow 2002). This enzyme hydrolyzes chromogenic peptides at arginine or lysine carboxyl 
terminals and plays a key role in the development and differentiation of the parasite during various life 
cycle stages (Beaulieu et al. 2010). In order to investigate the specific interactions from each ligand 
with Cruzipain (PDB: 3I06), we first identify the best pockets calculated from Metapocket server. The 
data-set suggested that the highest docking score resulted when the pocket used is characterized by the 
presence of amino acids residues: Lys17, Phe28, Glu50, Asp18, Asn47, Leu48, Ser49, Glu86, Asp87, 
Pro90, Tyr91, Ala15, Gln19, Val16, Thr185, Asp18, Ile31, Met52, Ser88, Thr85, Gln51 and Tyt89 
(Figure 1B). These amino acids residues were near to the enzyme surface. This site was defined as 
binding pocket for the docking runs. 
 
Molecular docking studies were performed on all hybrids 4a-k, to investigate the importance of the 
motif that contribute to T. cruzi cruzipain binding when docked into the selected pocket. All quinoline-
ligands showed similar binding affinities for the selected pocket (Table 3). Notably, the most active 
compound 4b showed the highest scoring pose (binding energy of -7.5 kcal/mol). The results from the 
docking analyses suggest a slowly reversible mechanism of inhibition that is aided by strong non-
covalent interactions. In general, the compounds docked showed the formation of significant 
interactions with residues within the binding pocket. Then, a closer look at the best possible binding 
pose of hybrid 4b (highly active molecule, CE50: 8.84 μg/mL) reveals that strong interactions into the 
active site, which are shown in Figure 4C, involved one hydrogen bond interaction between hydroxyl 
group of 4b and the Tyr89 and Glu86 residues; π–cation between Lys17 residue of the protein and the 
quinoline-ring motif of the compound. Hydrophobic interactions surrounded by side chains of 
predominantly nonpolar residues confers stability during the binding event in the pocket (Figure 4D). 
Table 3 summarizes the best binding energy per evaluated compound on T. cruzi cruzipain. Docking 
results suggest that hybrid 4b represents a novel hit cruzipain inhibitor that can be exploited for further 
analog design as potential antichagasic agents. Moreover, these findings are also supported by previous 
reports of active quinolines against this parasite protein target (Kaur et al 2010; Foley and Tilley 1998).  
 
 
 
 
Table 3 Best binding energy (in kcal/mol) of most favorable docked conformations  
based on AutoDock scoring. 
 
 
 PfLDH  T. cruzi cruzipain 
Ligand Best binding energy (kcal/mol) Best binding energy 
(kcal/mol) Site 1 a Site 2 b 
4ª -7.5 -6.6 -7.2 
4b -7.5 -6.3 -7.5 
4c -7.3 -6.5 -7.1 
4d -7.4 -6.6 -7.2 
4e -7.6 -6.7 -7.2 
4f -7.6 -6.5 -7.1 
4g -7.1 -6.4 -6.8 
4h -7.5 -6.3 -6.9 
4i -7.3 -6.2 -6.9 
4j -6.9 -6.5 -6.9 
4k -7.7 -6.5 -6.9 
NADH -9.7 N/A --- 
Chloroquine -7.4 -6.3 --- 
Amodiaquine -7.4 -6.8 --- 
Quinine -7.1 -6.5 --- 
Mefloquine -8.3 -7.5 --- 
                                                    
                              a NADH binding site 
                                                  b Allosteric binding site 
 
Drug-likeness prediction studies 
We calculated and analyzed various drug-likeness properties for the 11 quinoline-biphenyl hybrids. 
The prediction results are summarized in Table 4. All compounds showed typical values for the 
parameters analyzed, exhibiting suitable drug like characteristics. The predicted values are within the 
range of properties of 95% of currently known drugs. According to Lipinski’s rule of five (Lipinski et 
al. 1997, an orally active drug that has no more than one violation is acceptable) the tested hybrids 4a-k 
could be orally active drugs in human. It was observed that all the title compounds exhibited high 
human intestinal absorption (% HIA) and high percent of human oral absorption (% F) ranging from 80 
to 100%. Greater HIA and F values denote that the hybrids 4a-k could be better absorbed from the 
intestinal tract upon oral administration. Among the predicted physico-chemical properties, the 
molecular PSA is a descriptor that was shown to correlate well with passive molecular transport 
through membranes and allows the prediction of drug-membrane interactions. Calculated PSA (Ertl et 
al. 2000) values for compounds 4a-k showed high PSA values, suggesting that perhaps these polar 
compounds tend to have a greater affinity and good ability to penetrate through infected cells.  
 
Tabla 4 Physico-chemical and drug-like properties of compounds 4a-k 
 
 
Entry 
 
 
M.W a 
 
PSA b 
(7-200 Å2) 
n-Rot 
Bond 
(<15)   
Log Po/w  c 
(-2.0 – 6.5) 
Log KHSA d 
(-1.5 – 1.2) 
App. 
Caco-2 e 
(nm/s) 
(<25 poor >500) 
App. 
MDCK (nm/s) f 
(<25 poor >500) 
% HIA g 
<25% is 
poor 
Lipinski 
Rule of five 
(≤1) 
% F h 
(>80% is high) 
4a 205.259   10.336   1 4.468   0.468   8442 4962 100 0 >80 
4b 221.258 33.019 2 3.356 0.271 2542 1356 100 0 >80 
4c 235.285 18.817 2 4.141   0.422 8442 4962 100 0 >80 
4d 221.258 31.669 2 3.439 0.259 3490 1910 100 0 >80 
4e 223.249   10.337   1 4.555   0.515 8441 8973 100 0 >80 
4f 250.256   59.003   2 3.392 0.398 867 424 100 0 >80 
4g 265.311   22.558   3 4.192   0.375   9090 5376 100 0 >80 
4h 265.311 24.528 3 4.238 0.411 8348 4903 100 0 >80 
4i 265.311   26.363   3 4.220   0.397   8702 5128 100 0 >80 
4j 265.311   27.095   3 4.068   0.319   9180 5433 100 0 >80 
4k 265.311   27.008   3 4.152   0.371   8526 5016 100 0 >80 
 
a Molecular weight of the molecule; ; b Polar surface area (PSA) (7.0–200.0); c Predicted octanol–water partition coefficient (log Po/w) (–2.0 to 6.5); d Logarithm 
of predicted binding constant to human serum albumin (log KHSA) (-1.5 to 1.2); e Predicted human intestinal permeability model (App. Caco-2); f Apparent 
permeability across cellular membranes of Madin-Darby canine kidney (MDCK) cells; g Human intestinal absorption (% HIA) (>80% is high, <25% is poor); h is 
the fraction of an oral administered drug that reaches systemic circulation (percent of human oral absorption %F). 
 
 
In addition, lipophilicity influences a number of physiological properties, including transport through 
lipid bilayers, and therefore it is an important property that a drug should exhibit. LogP gives a measure 
of the lipophilicity of a compound and is a good indicator of permeability across the cell wall (Veber et 
al. 2002). In this study, all the tested compounds exhibited LogP values below 5, ranging from 3.346 to 
4.555, suggesting good permeability and permeation across the cell membrane of infected cells. 
Moreover, in silico artificial membrane permeation rate across Caco-2 cell monolayers or MDCK cells 
was calculated for all quinoline-hybrids derivatives. It was found that the passive transmembrane 
permeation of the novel compounds displayed good permeability values (from 1356 to 9180 nm/s), 
except for nitro-substituted 4f which displayed poor cell permeability values (less than 867 nm/s). 
Finally, the early prediction of plasma protein binding (calculated as log KHSA) has vital importance in 
the characterization of drug distribution in the systemic circulation. Unfavorable log KHSA values can 
represent a negative effect on clinical development of promising drug candidates for human parasitic 
diseases chemotherapy. For all compounds, were obtained high binding affinity values (more than 
0.25) compared to reference values taken from 95% of currently known drugs (Log KHSA from -1.5 to 
1.2).  
 
From the therapeutic point of view, the interpretation of predicted ADMET properties showed 
recommended values ranges for an ideal drug, demonstrating the potential of the hybrids 4a-k as 
therapeutic candidates to discover novel drugs for specific treatment for T. cruzi or P. falciparum 
infections. These in-silico ADMET predictions suggest that quinoline-biphenyl hybrids here reported 
follow the criteria for orally active drugs and thus represent a potential pharmacologically active 
framework that should be considered in progressing further potential hits.  
 
 
Conclusions 
The synthesis, in silico studies, antileishmanial, antitrypanosomal and antiplasmodial screening of 
eleven quinoline-biphenyl hybrids are reported. Five of them were active against L. (V) panamensis, 
two of them against T. cruzi  and four of them against P. falciparum with EC50 values lower than 20 
μg/mL. Hybrid 4a showed similar activity than meglumine antimoniate and compound 4b exhibited an 
activity similar to that of benznidazole. Hybrid 4k showed the best activity against P. falciparum. 
Studies on an animal model are needed to confirm the results observed in vitro. These compounds were 
toxic for mammalian U-937 cells, however  they may still have  potential  to  be  considered  as  
candidates  for  antileishmanial, antitrypanosomal and antiplasmodial drug development.  More studies 
on  toxicity  using  other  cell  lines  are  needed  to  discriminate whether  the  toxicity  shown  by  
these  compounds  is  specific against  tumor  or  non-tumor  cells. SAR study revealed the importance 
of hydroxyl group in 4-position of the phenyl group for antitrypanosomal activity. On the other hand, 
for antileishmanial activity the presence of substituents in the phenyl group decrease de activity. As 
regards antiplasmodial activity, our studies have shown that the presence of methoxyl groups in 3- and 
4-position and electron withdrawing groups in the 4-position are important in order to achieve 
biological action. 
. 
 
Molecular docking was used to investigate the in silico inhibition effects of the eleven quinoline-
biphenyl hybrids on two important antiparasitic drug targets (PfLDH and T. cruzi cruzipain enzymes). 
Docking studies against PfLDH structure suggest that the hybrids  could act as competitive inhibitors 
as they had higher binding energy than reference drugs, and close to the cofactor, NADH. In addition, 
the present findings further support that these molecules may be potentially inhibitors of  T. cruzi 
cruzipain enzyme and could be a potential molecular target for the evaluated compounds. 
Physicochemical and ADMET profile of these molecules, such as polar Surface area (PSA), LogP and 
the number of rotatable bonds (Nrot), membrane permeation rate, Plasma Protein Binding (KHSA) and 
human oral absorption (%F) showed that these hybrids have potential for an eventual development as 
oral agents and can be significant active drug candidates in search of better and safe antiprotozoal 
agents. 
 
 
Acknowledgments 
The authors thank Universidad de Antioquia (grant CODI IN656CE and CIDEPRO) for financial 
support. 
 
Conflict of interest 
The authors declare no conflict of interest.  
 
Supplementary data 
Supplementary data associated with this article can be found, in the online version 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
References 
Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M (2012) Leishmaniasis  
    Worldwide and Global Estimates of Its Incidence.  PLOS One  7: e35671 
Aponte J, Castillo D, Estevez Y, Gonzalez G, Arevalo J, Hammonda G, Sauvain M  (2010). In vitro 
and in vivo anti-Leishmania activity of polysubstituted synthetic chalcones. Bioorg Med Chem Lett 
20:100-103. 
Beaulieu C, Isabel E, Fortier A, Massé F, Mellon C, Méthot N, Black WC (2010). Identification of 
potent and reversible cruzipain inhibitors for the treatment of Chagas disease. Bioorg Med Chem Let 
20:7444-7449. 
Brenzan MA, Vaturu C, Dias B, Ueda T, Young MC, Côrrea AG, Alvim J Jr, dos Santos AO, Cortez 
DA (2008). Structure-activity relationship of (-) mammea A/BB derivatives against Leishmania 
amazonensis. Biomed Pharmacother 62:651-658.  
Brun R, Bühler Y, Sandmeier U, Kaminsky R, Bacchi CJ, Rattendi D, Lane S, Croft SL, Snowdon D, 
Yardley V, Caravatti G, Frei J, Stanek J, Mett H (1996). In Vitro Trypanocidal Activities of  New S-
Adenosylmethionine Decarboxylase Inhibitors. Antimicrob Agents Chemother 40:1442–1447 
Cardona-G W, Yepes AF, Herrera-R A (2018). Hybrid Molecules: Promising Compounds for the 
Development of New Treatments Against Leishmaniasis and Chagas Disease. Curr Med 
Chem 25:3637-3679 
Cardona W, Arango V, Domínguez J, Robledo S, Muñoz D, Figadère B, Velez ID, Sáez J (2013). 
Synthesis and leishmanicidal activity of new bis-alkylquinolines. J Chil Chem Soc 58:1709-1712. 
Chatelain E, Ioset JR (2011). Drug discovery and development for neglected diseases: the DNDi  
model. Drug Des Devel Ther 16:175-181. 
Chen M, Zhai L, Christensen SB, Theander TG, Kharazmi A (2001). A Inhibition of fumarate 
reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother 
45:2023-2029 
Coa JC, Castrillón W, Cardona W, Carda M, Ospina V, Muñoz JA, Vélez ID, Robledo SM (2015). 
Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids. Eur J 
Med Chem 101:746-753. 
Coa JC, García E, Carda M, Agut RD, Vélez ID, Muñoz JA, Yepes LM, Robledo SM, Cardona WI 
(2017). Synthesis, leishmanicidal, trypanocidal and cytotoxic activities of quinoline-chalcone and 
quinoline-chromone hybrids. Med Chem Res 26:1505-1414. 
García E,  Ochoa R, Vásquez I, Conesa-Milián L, Carda M, Yepes A, Vélez ID, Robledo SM, 
Cardona-GW (2019). Furanchalcone-biphenyl hybrids: synthesis, in silico studies, antitrypanosomal 
and cytotoxic activities. Med Chem Res 28:608-622. 
García E, Coa JC, Otero E, Carda M, Vélez ID, Robledo SM, Cardona WI (2018). Synthesis and 
antiprotozoal activity of furanchalcone–quinoline, furanchalcone–chromone and furanchalcone-
imidazole hybrids. Med Chem Res 27:497–511. 
Den Boer M, Argaw D, Jannin J, Alvar J (2011). Leishmaniasis impact and treatment access. Clin 
Microbiol Infect 17:1471-1477. 
Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M 
(2001). Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of  
visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65:685-689. 
Dunn C, Banfield M, Barker j, Higham C, Moreton K, Turgut-Balik D, Brady R, Holbrook JJ (1996). 
The Structure of Lactate Dehydrogenase from Plasmodium falciparum Reveals a New Target for 
Anti-Malarial. Design. Nat. Struct. Mol. Biol 3:912-915. 
Egan TJ (2001) Quinoline antimalarials. Expert Opin Drug Discov 11:185-209. 
Egan T, Ncokazi KK (2005) Quinoline antimalarials decrease the rate of beta-hematin formation. J 
Inorg Biochem 99:1532–1539. 
Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-
based contributions and its application to the prediction of drug transport properties. J Med Chem 
42:3714–3717. 
Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S (2004). Antimalarial drug discovery: Efficacy 
models for compound screening. Nat Rev Drug Discov 3:509-520. 
Finney  JD (1978). Probit  Analysis:  Statistical  Treatment  of  the  Sigmoid  Response  Curve,  3rd ed.; 
Cambridge University Press: Cambridge, UK, p. 550. 
Foley M, Tilley L (1998). Quinoline antimalarials: mechanisms of action and resistance and prospects 
for new agents. Pharmacol Ther 79:55–87.  
Franck X, Fournet A, Prina E, Mahieux R, Hocquemiller R, Figadère B (2004). Biological evaluation 
of substituted quinolones. Bioorg Med Chem Lett 14:3635-3638. 
Huang B (2009). MetaPocket: A Meta Approach to Improve Protein Ligand Binding Site Prediction. 
OMICS J. Integr Biol. 3:325-330. 
Insuasty B, Ramirez J, Becerra D, Echeverry C, Quiroga J, Abonia R, Robledo SM, Velez ID, Upegui 
Y, Muñoz JA, Ospina V, Nogueras M, Cobo J (2015). An efficient synthesis of a new caffeine-
based chalcones, pyrazolines and pyrazolo[3-4-b][1-4]diazepines as potential antimalarial, 
antitrypanosomal and antileishmanial agents. Eur J Med Chem 93:401-413 
Kaur K, Jain M, Reddy RP, Jain R (2010) Quinolines and structurally related heterocycles as 
antimalarials. Eur. J. Med. Chem 45:3245-3264. 
Keenan M, Chaplin JH (2015).  A new era for chagas disease drug discovery?  Prog Med Chem 
54:185- 
    230. 
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997). Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development settings. Adv 
Drug Deliv Rev 23:3-25. 
Liu L, Zhang Y, Wang Y (2005). Phosphine-Free Palladium Acetate Catalyzed Suzuki Reaction in 
Water. J Org Chem 70:6122-6125. 
Lombard MC, N'Da DD, Breytenbach JC, Smith PJ, Lategan CA (2011). Synthesis, in vitro 
antimalarial and cytotoxicity of artemisinin-aminoquinoline hybrids. Bioorg Med Chem Lett 
21:1683-1686. 
Londoño F, Cardona W, Alzate F, Cardona F, Vélez ID, Upegui Y, Ospina V, Muñoz JA, Robledo SM 
(2016). Antiprotozoal activity and cytotoxicity of extracts from Solanum arboreum and S. 
ovalifolium (Solanaceae). J Med Plants Res 10:100-107. 
Lord AM, Mahon MF, Lloyd MD, Threadgill MD (2009). Design, Synthesis, and Evaluation in Vitro 
of Quinoline-8-carboxamides, a New Class of Poly(adenosine-diphosphate-ribose)polymerase-1 
(PARP-1) Inhibitor. J Med Chem 52:868-877. 
Ma L, Chen J, Wang X, Liang X, Luo Y, Zhu W, Wang T, Peng M, Li S, Jie S, Peng A, Wei Y, Chen 
L (2011)  Structural modification of honokiol, a biphenyl occurring in magnolia officinalis: the 
evaluation of honokiol analogues as inhibitors of angiogenesis and for their cytotoxicity and 
structure-activity relationship. J Med Chem 54:6469-6481  
Menting J, Tilley L, Deady L, Ng K, Simpson R, et al. (1997). The antimalarial drug, chloroquine, 
interacts with lactate dehydrogenase from Plasmodium falciparum. Mol Biochem Parasitol 88:215–
224.  
Morris GM, Goodshell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998). Docking 
Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J Comput 
Chem 19:1639-1662. 
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009). 
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput 
Chem 30:2785-2791. 
Meunier B  (2008) Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 
41:69 77 
Nakayama H, Loiseau PM, Bories C, De Ortiz ST, Schinini A, Serna E, Rojas de Arias A, Fakhfakh 
MA,  Franck X, Figadère B, Hocquemiller R, Fournet A (2005). Efficacy of orally administered 2-
substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob. 
Agents Chemother 49 :4950-4956 
Ncokazi KK, Egan TJ (2005). A colorimetric high-throughput beta-hematin inhibition screening assay 
for use in the search for antimalarial compounds. Anal Biochem 338:306–319. 
Read J, Wilkinson K, Tranter R, Sessions R, Brady R (1999). Chloroquine binds in the cofactor 
binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem 274:10213–10218.  
Sajid M, McKerrow JH (2002). Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 
120:1-21. 
Shaveta, Mishra S, Singh P (2016). Hybrid molecules: The privileged scaffolds for various 
pharmaceuticals. Eur J Med Chem 124:500-536 
Suresh K, Sandhya B, Himanshu G (2009). Biological activities of quinoline derivatives. Mini-Rev 
Med     Chem 9:1648-1654. 
Otero E, García E, Palacios G, Yepes LM, Carda M, Agut R, Vélez ID, Cardona WI, Robledo SM 
(2017).  Triclosan-caffeic acid hybrids: Synthesis, leishmanicidal, trypanocidal and cytotoxic 
activities. Eur J Med Chem 141:73-83. 
Otero E,  Robledo SM,  Díaz S, Carda M, Muñoz D, Paños J, Vélez ID,  Cardona W (2014). Synthesis 
and leishmanicidal activity of cinnamic acid esters: structure–activity relationship. Med Chem Res 
23:1378-1386. 
Otto HH, Schirmeister T (1997) Cysteine Proteases and Their Inhibitors. Chem Rev 97:133-172. 
Palit P, Paira P, Hazra A, Banerjee S, Das Gupta A, Dastidar S, Mondal N (2009) Phase transfer 
     catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis 
     and in vitro antibacterial evaluation. Eur J Med Chem 44:845-853. 
Patrick, G.L.  2013. An Introduction to Medicinal Chemistry, fifth ed., Oxford University Press, pp. 1-
14. 
Pierson JT, Dumetre A, Hutter S, Delmas F, Laget M, Finet JP, Azas N, Combes S (2010). Synthesis 
and antiprotozoal activity of 4-arylcoumarins. Eur J Med Chem 45:864-869. 
Pulido SA, Muñoz DL, Restrepo AM, Mesa CV, Alzate JF, Vélez ID, Robledo SM (2012). 
Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and 
in vivo screening of antileishmanial drugs. Acta Trop 122:36-45. 
Taylor VM, Cedeño DL, Muñoz DL, Jones MA, Lash TD, Young AM, Constantino MH, Esposito N, 
Vélez ID, Robledo SM (2011). In vitro and in vivo studies of the utility of dimethyl and diethyl 
carbaporphyrin ketals in treatment of cutaneous leishmaniasis. Antimicrob Agents Chemother 
55:4755-4764. 
Tempone A, Melo A, Da Silva P, Brandt C, Martinez F, Borborema A (2005). Synthesis and 
    antileishmanial activities of novel 3-substituted quinolones. Agents chemother 49:1076-1080.   
Trott O, Olson AJ (2010). AutoDock Vina: Improving the Speed and Accuracy of Docking with a New 
Scoring Function, Efficient Optimization, and Multithreading. J Comput Chem 3:455-461. 
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002). Molecular properties 
that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623. 
Vennerstrom J, Nuzum E, Miller R, Dorn A, Gerena L, et al. (1999). 8-Aminoquinolines active against 
blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents 
Chemother 43:598–602. 
Vieira NC, Herrenknecht C, Vacus J, Fournet A, Bories C, Figadère B, Espindola LS, Loiseau PM 
(2008). Selection of the most promising 2-substituted quinoline as antileishmanial candidate for 
clinical trials Biomed Pharmacother 62:684-689. 
World Health Organization (WHO, 2019a) Leishmanisis. https://www.who.int/leishmaniasis/en/. 
(accessed 04 March 2019) 
World Health Organization (WHO, 2019b) Chagas disease (American Trypanosomiasis). 
http://www.who.int/news-room/fact-sheets/detail/chagasdisease-(american-trypanosomiasis).  
Accessed 04 March 2019 
World Health Organization (WHO, 2018a). Neglected tropical diseases. Available online:      
http://www.who.int/neglected_diseases/diseases/en/ (accessed on 20 June 2018) 
World Health Organization (WHO, 2018b). World Malaria Report 2018. Available online:       
https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/ 
(accessed on 04 March 2019) 
Yang X, Xu G, Tang W (2016). Efficient Synthesis of Chiral Biaryls Via Asymmetric Suzuki-Miyaura 
Cross-coupling of Ortho-bromo Aryl Triflates. Tetrahedron 72:5178-5183. 
